Clinical AI on Trial: Shadow Tools and Governance Gaps | Newsday with Yaw Fellin and Matt Troup episode artwork

EPISODE · Jul 20, 2026 · 30 MIN

Clinical AI on Trial: Shadow Tools and Governance Gaps | Newsday with Yaw Fellin and Matt Troup

from The 229 Podcast

July 20, 2026: A new Nature of Medicine study claims general-purpose LLMs outperform specialized clinical AI, but is that the right benchmark to begin with? Bill and Drex are joined by Yaw Fellin, General Manager of UpToDate at Wolters Kluwer, and Matt Troup, Clinical Strategy Principal at Abridge, to break down what those benchmarks actually measure, why shadow AI is already spreading through health systems, and what "clinical grade" really means. Plus: the first-ever look at UpToDate's new drug dosing feature in Expert AI, and why automaticity bias may be the next liability crisis hiding in plain sight.Key Points:03:18 Nature Study Breakdown10:25 Shadow AI Reality Check18:37 Transparency and Provenance23:40 Human in the Loop WrapKeep up to date on the latest in health IT:https://thisweekhealth.com/news/X: This Week HealthLinkedIn: This Week HealthDonate: Alex’s Lemonade Stand: Foundation for Childhood Cancer

Episode metadata supplied by the publisher feed · Published Jul 20, 2026

Embed this episode

NOW PLAYING

Clinical AI on Trial: Shadow Tools and Governance Gaps | Newsday with Yaw Fellin and Matt Troup

0:00 30:38

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The 229 Podcast?

This episode is 30 minutes long.

When was this The 229 Podcast episode published?

This episode was published on July 20, 2026.

Can I download this The 229 Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!